MedTrace Logo

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

NCT06836063 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2026-04-07

No results posted yet for this study

Summary

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Ropanicant

Tablet dosage form, twice a day

DRUG

Placebo

Matching placebo tablets, twice a day

Sponsors & Collaborators

  • Suven Life Sciences Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-02-23
Completion
2026-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06836063 on ClinicalTrials.gov